Cost-Effectiveness of Women’s Vaccination Against HPV: Results for Czech Republic

Abstract

This paper assesses the cost-effectiveness of HPV vaccination in the Czech Republic, focusing on cervical cancer prevention. It compares the cost-effectiveness of existing reimbursement policies with proposed changes. A homogeneous multistate Markov model, based on public health insurance data, simulates disease progression. Our findings show that increasing immunization coverage from 65.8% to 80% is cost-effective, meeting the 1.2 million CZK per quality-adjusted life year threshold. Extending vaccination eligibility from age 13 to 13-15 years old, while boosting coverage, also proves cost-effective. These results support the economic viability of the proposed policy enhancements for increasing HPV vaccination among women.